EMA Validates Hengrui Pharma's Fuzuloparib MAA
Hengrui Pharma has announced EMA validation of MAA for Wevdury (fuzuloparib) in combination with abiraterone for metastatic castration-resistant prostate cancer.
Professor Dingwei | 12/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy